Janssen Pharmaceutica N.V. To Present New Simeprevir Data At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORK, Ireland--(BUSINESS WIRE)--New data from the clinical development programme for Janssen’s protease inhibitor simeprevir in the treatment of genotype 1 or genotype 4 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease will be presented at The International Liver Congress™ of the European Association for the study of the Liver (EASL). The International Liver Congress™ 2014 will take place from April 9-13 in London.

Help employers find you! Check out all the jobs and post your resume.

Back to news